Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis

Résumé fourni par la source

Although Afro-Caribbean (AC) race has been associated with worse outcomes in many cardiovascular diseases, its potential association with transthyretin cardiac amyloidosis (ATTR-CA) is less understood. We aimed to assess the relationship between race and serum biomarkers, adverse cardiac remodeling, and outcomes in AC vs white ATTR-CA patients. 114 AC and 117 white patients confirmed ATTR-CA who underwent cardiac magnetic resonance (CMR) exam were identified. The relationship between race and the primary endpoint-defined by all-cause mortality or heart failure hospitalization-was assessed using Cox regression analysis. ATTR disease stage was significantly higher at diagnosis in AC vs white patients (p < 0.0001). Left (p = 0.001) and right ventricular ejection fractions (p = 0.0002) were lower and extracellular volume (58% vs 50%) higher in AC vs white patients. At a median follow up time of 365 (IQR, 97-879) days, 44% of patients had experienced the primary endpoint. AC race was strongly associated with the primary endpoint compared with White patients (HR 2.83, 95% CI 1.92-4.23, p < 0.0001). AC patients were found to be at more advanced disease stages at the time of ATTR-CA diagnosis and experienced poor outcomes more frequently, highlighting the need for targeted strategies to address these health inequities.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.